A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 17300 participants.

Also called NCT06292013

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 17,300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06292013
  • EudraCT 2023-509190-23
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, Denmark, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Mexico, Netherlands, Poland, Puerto Rico, Romania, Slovakia, South Korea, Spain, Taiwan, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06292013. Randomized; double masking; primary purpose treatment. Start 2024-03-05 (actual); primary completion 2029-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Condition
Atherosclerotic Cardiovascular Disease (ASCVD)
Condition
Elevated Lp(a)
Intervention (Drug)
Lepodisiran Sodium
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct06292013
Content hash
0d3ebb4d791d4016a9eae3bb3f77d564eb28e62d6aed1f17c9374ec3c2d8286a